CME: Distilling Modern Medical Approaches in Advanced NSCLC: Precision, Performance, & Parallels with Patients

Distilling Modern Medical Approaches in Advanced NSCLC: Precision, Performance, & Parallels with Patients

Distilling Modern Medical Approaches in Advanced NSCLC: Precision, Performance, & Parallels with Patients
RestartResume
Discerning treatment options for advanced NSCLC patients without targetable activating mutations that had progressed on prior platinum-based therapy

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Lung and bronchus cancer remain the leading cause of cancer-related deaths in the United States among both men and women. The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, the anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 gene rearrangements, and BRAF has led to an improvement in overall survival and progression-free survival by identifying subgroups of patients who benefit from targeted treatment; however, most NSCLC tumors lack these mutations.

    NSCLC is a highly active research area and its treatment is rapidly evolving. The algorithm for the treatment of metastatic NSCLC has become increasingly complex as new therapies are being developed, including advances in the treatment of patients with metastatic NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, or chemotherapy in combination with immunotherapy, including NSCLC that has progressed rapidly on initial therapy.

    Through real-world clinical cases, this activity will review available treatment options and guideline recommendations for patients with advanced NSCLC without targetable activating mutations that has progressed on initial platinum-based therapy, or immunotherapy combined with chemotherapy, and available data that can inform treatment of NSCLC that progresses rapidly on initial therapy. Discussion will include real-world patient cases and clinical challenges including how the experts discerned the best treatment approaches based upon disease progression patterns, prior lines of therapy, unique patient characteristics, and wading through the vast amount of current/emerging evidence to arrive at the optimal treatment plan with their patients.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify treatment options for patients with metastatic NSCLC without targetable activating mutations that progresses on initial therapy that is platinum-based, or immunotherapy combined with chemotherapy
    • Select the most appropriate therapy according to guideline recommendations for patients with metastatic NSCLC without targetable activating mutations that has progressed on initial therapy
    • Integrate appropriate treatment options for advanced NSCLC without targetable activating mutations that has progressed rapidly on or after platinum-based first-line therapy using available data
    • Apply evidence-based data to inform optimal sequencing of treatments for patients who are chemo-refractory to first line therapy
  • Target Audience

    This activity is intended for thoracic oncologists, medical oncologists, pulmonologists, pathologists, and other medical professionals who treat or manage advanced NSCLC.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Robert Mocharnuk, MD

     Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

    Joshua Bauml, MD

    Joshua Bauml, MD, reported a financial interest/relationship or affiliation in the form of Research grant: Takeda Oncology; Bayer HealthCare, Inc; Janssen Oncology; AstraZeneca Pharmaceuticals LP; Merck & Co, Inc; Incyte Corp; Carevive; and Novartis Pharmaceuticals Corp. Received income in any amount from: Bristol-Myers Squibb Co; AstraZeneca Pharmaceuticals LP; Celgene Corp; Merck & Co, Inc; Janssen Oncology; Genentech, Inc; Guardant Health, Inc; Boehringer Ingelheim; and Takeda Oncology. 

    The following AXIS planners and managers, Jocelyn Timko hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.  Linda Gracie-King, MS, reports her spouse has a financial interest/relationship or affiliation in the form of Common stock:Exelixis.  Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Accreditation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

  • Fee

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Global Oncology Academy newsletters.
Comprehensive Oncology Education.

Better education for a better you.

* Required
Optional

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free